Researcher who sued to prevent retractions now has 12

A diabetes researcher who once sued a publisher to prevent several retractions has just issued his 12th.

The latest retraction, like several others for Mario Saad, appears in the journal Diabetes. Although in the past Saad expended considerable effort to protect four other Diabetes papers from this same fate, the latest retraction was initiated by the authors, citing several duplicated images. The American Diabetes Association had flagged the 2009 paper with an expression of concern earlier this year.

In 2015, Saad brought a lawsuit against the ADA, claiming that it “wrongfully published” four expressions of concerns in its flagship journal Diabetes, in an attempt to prevent the papers from being retracted. He lost, and the papers were retracted in 2016.

The lawsuit also did nothing to deter the ADA from flagging other potentially problematic papers with expressions of concerns, including the latest 2009 Diabetes paper, on which Saad is last and corresponding author.  Continue reading Researcher who sued to prevent retractions now has 12

PLOS upgrades flag on controversial PACE chronic fatigue syndrome trial; authors “surprised”

PLOS ONE has issued an expression of concern after the authors of a controversial study about chronic fatigue syndrome declined to share some of their data.

In an unusual move, the journal included the authors’ response to the expression of concern (EOC), in which they strongly argue against the notice, and “do not accept that it is justified.”

In 2015, following public requests to review the data, the journal issued an “editor’s note” on the paper, noting the journal’s policy that authors make data and materials available.

There have been numerous requests for data from the “PACE” trial, as the clinical trial is known. Patients and advocates have long disputed the results, arguing that suggesting cognitive behavior and graded exercise therapy could cause harm.

In the latest notice, the journal says it consulted two editorial board members about the paper, a 2012 sub analysis of a controversial clinical trial on chronic fatigue syndrome. The journal then asked the authors to provide the data behind five tables, which would enable researchers to replicate the cost-effectiveness analyses the authors report for different therapies — including graded exercise therapy, which some patient advocates believe could be harmful.

As with previous requests for data, the authors refused to provide it, citing patient confidentiality and consent. The notice explains:

Continue reading PLOS upgrades flag on controversial PACE chronic fatigue syndrome trial; authors “surprised”

Author objects to retraction after he says journal ignored his queries for three years

In 2014, a journal contacted researcher Denis Rousseau about one of his papers that had just been published online ahead of print, raising some concerns. According to Rousseau, he sent the journal a corrected figure “almost immediately,” which he believed addressed the issue.

Rousseau, a cell biologist at the University Joseph Fourier in Grenoble, France, said he then contacted the journal many times over the next three years to ask about the status of the paper — which never ended up in print — but heard nothing back.

Three years passed.

In March, the publisher finally contacted Rousseau, this time to ask him to issue a formal retraction for the paper. And despite his objections, Molecular and Cellular Biology published a sparse retraction notice, which provides little information about what went wrong:

Continue reading Author objects to retraction after he says journal ignored his queries for three years

Peer review in 2030: New report hopes it’s faster, more transparent, and more diverse

Elizabeth Moylan
Rachel Burley

Over the decades, the concept of peer review has changed dramatically – so what does the future hold? That’s a question examined in a new report issued today by BioMed Central and Digital Science, based on discussions held during the SpotOn London conference. (Disclosure: Our co-founder Ivan Oransky spoke there.) We spoke with Elizabeth Moylan, Senior Editor Research Integrity at BioMed Central, and Rachel Burley, Publishing Director at BioMed Central about the central question posed by the report: What will peer review look like in the year 2030?

Retraction Watch: People have many complaints about peer review. What do you think are its most pressing flaws?

Continue reading Peer review in 2030: New report hopes it’s faster, more transparent, and more diverse

“Remarkable” it was ever accepted, says report: Science to retract study on fish and microplastics

Science is retracting a paper about how human pollution is harming fish, after months of questions about the validity of the data.

The move, first reported by the news side of Science on Friday, follows a new report from a review board in Sweden that concluded the authors were guilty of “scientific dishonesty,” and the paper should be “recalled.”

The report had some strong words for the journal and the university that conducted a preliminary investigation:

Continue reading “Remarkable” it was ever accepted, says report: Science to retract study on fish and microplastics

University suggests journal correct diabetes paper. Publisher retracts it.

After a publisher learned there may be issues with a 2008 diabetes paper, it asked the author’s university to investigate. The university found evidence of image duplication, and asked the journal to consider correcting the paper.

Instead, the journal has retracted it.

The backstory involves diabetes researcher Kathrin Maedler, who has one previous retraction, as well as multiple corrections. Even the paper in question, published in Diabetes, received an erratum in 2014 regarding a duplicated image, as well as an expression of concern last August after the American Diabetes Association questioned “the reliability of the data” in both the article and erratum.

According to the expression of concern, the ADA asked the University of Bremen to investigate the issues in the paper. In October, the University of Bremen concluded that several duplications present in her work were the result of negligence, not misconduct.

To resolve the issues, the university’s rector recommended that the authors publish a second erratum with corrected figures. But after conducting its own review, the ADA overruled the university, opting instead to retract the paper:

Continue reading University suggests journal correct diabetes paper. Publisher retracts it.

Weekend reads: New calls for retraction; more on fake peer review; how long does peer review take?

The week at Retraction Watch featured a look at how long journals take to respond to retraction requests, and news of a $10 million settlement for research misconduct allegations. Here’s what was happening elsewhere: Continue reading Weekend reads: New calls for retraction; more on fake peer review; how long does peer review take?

Former rising star found guilty of misconduct issues 2nd retraction

A once-lauded researcher in the field of infectious disease — who has since been found guilty of misconduct — has retracted a second paper.

Last year, the University of Dundee in Scotland investigated and ultimately concluded that Robert Ryan — whose work focused on infections that can be deadly in people with lung diseases such as cystic fibrosis — had committed “serious research misconduct,” affecting multiple publications. After appealing the decision, Ryan resigned.

We covered his first retraction earlier this month, which cited multiple instances of image duplication. Now Ryan has retracted his second paper, published in 2011 in Journal of Bacteriology, also due to image problems.

Here’s the retraction notice: Continue reading Former rising star found guilty of misconduct issues 2nd retraction

$200M research misconduct case against Duke moving forward, as judge denies motion to dismiss

A Federal U.S. court in North Carolina has denied a motion to dismiss a major lawsuit filed against Duke University and two former employees, allowing the case to go forward.

Last year, the U.S. District Court of the Western District of Virginia unsealed a whistleblower lawsuit filed by another former employee at Duke against the university, a biologist and her former supervisor, alleging they included fraudulent data in applications and reports involving more than 60 grants. The total amount: $200 million. If successful, Duke may have to refund three times the amount of allegedly ill-gotten gains, and the whistleblower could himself receive millions.

The researcher, Erin Potts-Kant, her supervisor William Michael Foster, and Duke all filed motions to dismiss; this week, that motion was denied.

Continue reading $200M research misconduct case against Duke moving forward, as judge denies motion to dismiss

Harvard teaching hospital to pay $10 million to settle research misconduct allegations

Piero Anversa

Brigham and Women’s Hospital and its parent healthcare network have agreed to pay $10 million to the U.S. government to resolve allegations it fraudulently obtained federal funding.

The case, which involves three former Harvard stem cell researchers, dates back several years. In 2014, Circulation retracted a paper by Piero Anversa, Annarosa Leri, and Jan Kajstura, among others, amidst a university investigation into misconduct allegations. Anversa and Leri — whose lab was described as filled with “fear” by one former research fellow — later sued the hospital for notifying journals of that investigation. They lost.

In the agreement announced today by the Department of Justice (DOJ), Partners Healthcare and Brigham and Women’s Hospital have agreed to pay the government $10 million to settle allegations that the researchers fraudulently obtained funding from the National Institutes of Health:

Continue reading Harvard teaching hospital to pay $10 million to settle research misconduct allegations